Short Interest in Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Increases By 3,625.0%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 596 shares, a growth of 3,625.0% from the April 30th total of 16 shares. Based on an average daily volume of 6,288 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ascentage Pharma Group International in the third quarter worth $96,000. ABC Arbitrage SA acquired a new stake in shares of Ascentage Pharma Group International in the third quarter worth $204,000. Citadel Advisors LLC acquired a new stake in shares of Ascentage Pharma Group International in the third quarter worth $383,000. Hsbc Holdings PLC acquired a new stake in shares of Ascentage Pharma Group International in the second quarter worth $391,000. Finally, UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after acquiring an additional 10,988 shares during the period.

Analysts Set New Price Targets

AAPG has been the subject of several research reports. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a research report on Monday, April 6th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 price target for the company. Finally, BTIG Research reaffirmed a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to MarketBeat, Ascentage Pharma Group International currently has a consensus rating of “Buy” and an average price target of $46.67.

Ascentage Pharma Group International Stock Performance

Shares of NASDAQ AAPG traded up $0.44 during midday trading on Wednesday, reaching $20.57. The company had a trading volume of 10,113 shares, compared to its average volume of 6,116. The business’s 50-day simple moving average is $23.23 and its 200 day simple moving average is $25.90. Ascentage Pharma Group International has a 1 year low of $18.56 and a 1 year high of $48.45. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) earnings per share (EPS) for the quarter. The business had revenue of $24.72 million for the quarter. On average, equities research analysts expect that Ascentage Pharma Group International will post -1.09 earnings per share for the current year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.